Promarker®Endo featured on 9NEWS Perth
We're pleased to share 9NEWS’s coverage of Proteomics International's recent milestone: the successful refinement and independent validation of our PromarkerEndo blood test. The broadcast features Parinaz Irani, a member of our PromarkerEndo Patient Advisory Group, sharing her lived experience of endometriosis, alongside insights from our CEO, David Morris, and footage from inside our Perth laboratory.
Promarker®Endo is being developed to provide additional information to support the clinical assessment of patients with suspected endometriosis, with David citing the potential acceleration the test could bring to diagnosis process.
Proteomics expects to make the PromarkerEndo test commercially available during FY27 Q3, subject to applicable clinical deployment and regulatory requirements. Once available, the test is expected to be accessible through physician referral.
We thank Parinaz for sharing her perspective and 9NEWS Perth for highlighting this important area of women's health research.
Promarker®Endo in The West Australian
The coverage follows a dedicated article in The West Australian (subscription required to read), which examines the significant burden of endometriosis, the challenges of diagnosis and the potential role of PromarkerEndo in helping clinicians assess patients with suspected disease. The article also features reproductive medicine expert Professor Roger Hart, who discusses the test’s potential to reduce diagnostic delays and reliance on invasive laparoscopic procedures.
What's next for Promarker®Endo?
Proteomics expects to make Promarker®Endo commercially available in the third quarter of FY27, subject to applicable clinical deployment and regulatory requirements. Once available, the test is expected to be accessible via physician referral.
We remain focused on advancing Promarker®Endo towards commercialisation and will continue to keep investors informed as we reach key milestones.